1. Successful Treatment of Adenoid Cystic Carcinoma with the Application of a High-Dose Stereotactic Body Radiotherapy Boost
- Author
-
Bolesław Pilecki, Natalia Amrogowicz, Dorota Księżniak-Baran, Agnieszka Pietruszka, Paweł Polanowski, Karolina Gajda, Krzysztof Składowski, Aleksandra Grządziel, and Ewa Chmielik
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Adenoid cystic carcinoma ,medicine.medical_treatment ,radiosurgery boost ,Case Report ,Case presentation ,lcsh:RC254-282 ,Stereotactic radiotherapy ,03 medical and health sciences ,0302 clinical medicine ,Conventional radiotherapy ,medicine ,adenoid cystic carcinoma ,nasopharynx tumour ,Radical treatment ,business.industry ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Cancer treatment ,Radiation therapy ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,stereotactic radiotherapy ,Radiology ,business ,Stereotactic body radiotherapy - Abstract
Background: Adenoid cystic carcinoma (ACC) should be treated with a surgical procedure. Unfortunately, in some cases, such procedures are impossible to perform. In that event, radiotherapy can be used as a form of radical treatment, although ACC is established as a radio- and chemoresistant tumour. Therefore, unconventional fractionated radiotherapy needs to be considered. Case presentation: Here, we present a case study of a patient with an unresectable tumour of the choanae and nasopharynx treated with a stereotactic radiotherapy boost in combination with conventional radiotherapy. We achieved complete clinical regression after application of a 1 × 18 Gy boost followed by conventional radiotherapy at 50 Gy in 25 fractions. The early and late tolerance of this treatment were positive. During the 2-year follow-up, local and distant recurrence were not detected. Conclusions: This case represents an individualized, modern and safe approach to unresectable ACC. This is one of the first cases to show the use of a combination of stereotactic and conventional radiotherapy in radical, conservative cancer treatment.
- Published
- 2021